![]() In August, Moderna sued Pfizer and BioNTech for patent infringement related to the mRNA technology used in its COVID-19 vaccine. Multiple lawsuits have previously been filed related to the coronavirus vaccines and the technology that made it possible.įor example, in February Moderna paid the federal government $400 million for a chemical technique it employed in its COVID-19 vaccine. ![]() Patent infringement lawsuits are not uncommon in the realm of biotechnology and pharmaceuticals. These therapies often involve gene silencing, which silences a gene to stop it from. “Unfortunately, these big pharma companies have failed to give Promosome what it deserves.” types include mRNA, ASOs, miRNA, Ribosomal RNA, siRNA and. “Our client’s cutting-edge technology has helped spare hundreds of millions of people from the harmful effects of COVID-19,” said Bill Carmody, lead lawyer on the matter and partner at the firm Susman Godfrey. Pfizer and BioNTech brought in $37.8 billion from sales of its COVID-19 vaccine, Comirnaty, last year. ![]() Moderna netted $18.4 billion in sales for its coronavirus vaccine last year, according to SEC filings. Please note that the code must be integrated into the HTML code (not only the text) for WordPress pages and other CMS sites.In each complaint Promosome seeks “to receive its rightful share of the tens-of-billions in revenues,” each company “already has earned and countless billions it will earn by willfully infringing the ’179 Patent.” Our standard is 660 pixels, but you can customize how the statistic is displayed to suit your site by setting the width and the display size. Simply copy the HTML code that is shown for the relevant statistic in order to integrate it. Yes, Statista allows the easy integration of many infographics on other websites. This decision drew skepticism from human rights groups due to its focus on profit instead of sharing of knowledge and technology with local facilities.Ĭan I integrate infographics into my blog or website? In February of 2022, BioNTech announced the planned deployment of mobile vaccine factory containers to Africa to increase vaccination rates. For example, BioNTech generated 19 billion Euros in revenue with its vaccine alone in 2021, while Moderna made $18 billion in the same year. While vaccine makers like BioNTech and Moderna cite lacking capacities and qualifications in African, Latin American and Asian countries for their stance against the suspension of coronavirus vaccine patents, the enormous profit margins are likely another factor in the equation. When injected, mRNA vaccines teach your cells to make a piece of a protein that is found on the surface of the virus that causes COVID-19. The African continent houses eight such facilities in countries like Egypt and Tunisia, while Brazil is the country with the most qualifying factories in Latin America. Unlike many vaccines that require an injection with a weakened or inactivated virus, two COVID-19 vaccines use a new technology: messenger ribonucleic acid (mRNA). The majority of these facilities are located in India (55) and China (34), many of which have already produced the corresponding country's own vaccines like Covaxin, Covilo or CoronaVac, which in turn have not yet been approved for use in the West. With the corresponding knowledge transferred, every company on the list put together by MSF fulfills the requirement for "good manufacturing praxis" (GMP) or has already exported a sterile pharmaceutical product to either the European Union or the United States. ![]() As our chart based on data collected by Médecins sans Frontières (MSF) shows, 120 non-Western pharmaceutical facilities would have theoretically been ready to mass-produce highly effective mRNA vaccines at the end of 2021.Īs MSF points out, mRNA vaccines are simpler to produce and "more predictable and easier to transfer to other manufacturers" than vaccines relying on older technology. Both measures were largely opposed by the European Commission and pharmaceutical companies like Moderna and BioNTech. Description: Getting vaccinated For information about COVID-19 vaccine, visit: cdc.gov/coronavirus/vaccines. ![]() This stark contrast is the result of a variety of reasons, but experts agree that there are two key ways to speed up vaccine production and deployment in economically poorer African, Latin American and Asian countries: Technology transfer and the suspension of vaccine patents at least for the duration of the pandemic. The gap between low and upper middle income countries, in particular, seems unbridgable, with vaccination rates of 16 percent in the former and 79 percent in the latter. According to calculations by Our World in Data, 61 percent of the world population has received two doses of one of the several coronavirus vaccines available on the market. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |